drugset / Trial / NCT00517049

A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)

NCT00517049

Phase 2 Completed 49 enrolled Genentech, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This Phase II, single-arm, open-label, multicenter trial is designed to evaluate the safety, efficacy, and pharmacokinetics of PRO95780 when combined with rituximab in patients with follicular, CD20-positive B-cell NHL that has progressed following previous rituximab therapy.

Timeline

Start
2008-03
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PRO95780 Unknown Intravenous
Background Rituximab Monoclonal antibody Intravenous

Indications